(NASDAQ: ENGN) Engene Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.21%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.48%.
Engene Holdings's earnings in 2025 is -$94,721,000.On average, 12 Wall Street analysts forecast ENGN's earnings for 2025 to be -$111,664,610, with the lowest ENGN earnings forecast at -$111,372,817, and the highest ENGN earnings forecast at -$109,115,260. On average, 12 Wall Street analysts forecast ENGN's earnings for 2026 to be -$124,257,786, with the lowest ENGN earnings forecast at -$140,470,220, and the highest ENGN earnings forecast at -$101,052,556.
In 2027, ENGN is forecast to generate -$97,730,210 in earnings, with the lowest earnings forecast at -$121,406,404 and the highest earnings forecast at -$64,501,631.